Edmond Lam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Edmond Lam has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Usha D. Hemraz
Department of Chemistry, University of Alberta, 11227 Saskatchewan Drive, Edmonton, Alberta, T6G 2G2, Canada
3 shared publications - Bassel Akache
National Research Council Canada, Human Health Therapeutics, Ottawa, Canada
2 shared publications - Blair A. Harrison
Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada
2 shared publications - Felicity C. Stark
Human Health Therapeutics, National Research Council of Canada, Ottawa, ON K1A 0R6, Canada
2 shared publications - Gerard Agbayani
Ottawa Hospital Research Institute, Ottawa, ON, Canada
2 shared publications - Lakshmi Krishnan
Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada
2 shared publications
Latest Publications
- Open Access
Characterization of Virulent T4-Like Acinetobacter baumannii Bacteriophages DLP1 and DLP2
The world is currently facing a global health crisis due to the rapid increase in antimicrobial-resistant bacterial infections. One of the most concerning pathogens is Acinetobacter baumannii, which is listed as a Priority 1 pathogen by the World Health Organization. This Gram-negative bacterium has many intrinsic antibiotic resistance mechanisms and the ability to quickly acquire new resistance determinants from its environment. A limited number of effective antibiotics against this pathogen complicates the treatment of A. baumannii infections. A potential treatment option that is rapidly gaining interest is “phage therapy”, or the clinical application of bacteriophages to selectively kill bacteria. The myoviruses DLP1 and DLP2 (vB_AbaM-DLP_1 and vB_AbaM-DLP_2, respectively) were isolated from sewage samples using a capsule minus variant of A. baumannii strain AB5075. Host range analysis of these phages against 107 A. baumannii strains shows a limited host range, infecting 15 and 21 for phages DLP1 and DLP2, respectively. Phage DLP1 has a large burst size of 239 PFU/cell, a latency period of 20 min, and virulence index of 0.93. In contrast, DLP2 has a smaller burst size of 24 PFU/cell, a latency period of 20 min, and virulence index of 0.86. Both phages show potential for use as therapeutics to combat A. baumannii infections.
Open AccessCharacterization of Virulent T4-Like Acinetobacter baumannii Bacteriophages DLP1 and DLP2
The world is currently facing a global health crisis due to the rapid increase in antimicrobial-resistant bacterial infections. One of the most concerning pathogens is Acinetobacter baumannii, which is listed as a Priority 1 pathogen by the World Health Organization. This Gram-negative bacterium has many intrinsic antibiotic resistance mechanisms and the ability to quickly acquire new resistance determinants from its environment. A limited number of effective antibiotics against this pathogen complicates the treatment of A. baumannii infections. A potential treatment option that is rapidly gaining interest is “phage therapy”, or the clinical application of bacteriophages to selectively kill bacteria. The myoviruses DLP1 and DLP2 (vB_AbaM-DLP_1 and vB_AbaM-DLP_2, respectively) were isolated from sewage samples using a capsule minus variant of A. baumannii strain AB5075. Host range analysis of these phages against 107 A. baumannii strains shows a limited host range, infecting 15 and 21 for phages DLP1 and DLP2, respectively. Phage DLP1 has a large burst size of 239 PFU/cell, a latency period of 20 min, and virulence index of 0.93. In contrast, DLP2 has a smaller burst size of 24 PFU/cell, a latency period of 20 min, and virulence index of 0.86. Both phages show potential for use as therapeutics to combat A. baumannii infections.
- Top Cited Papers
- 10 May 2022
- Published by Elsevier in Carbohydrate Polymers
- Vol. 291, 119590
Starch modification for non-food, industrial applications: Market intelligence and critical review
- 10 May 2022
- Published by Elsevier in Carbohydrate Polymers
- Vol. 291, 119590
Top Cited PapersStarch modification for non-food, industrial applications: Market intelligence and critical review
- Open Access
- 22 June 2021
- Published by MDPI AG in Nanomaterials
- Vol. 11 (7) , 1641
Preparation and Surface Functionalization of Carboxylated Cellulose Nanocrystals
In recent years, cellulose nanocrystals (CNCs) have emerged as a leading biomass-based nanomaterial owing to their unique functional properties and sustainable resourcing. Sulfated cellulose nanocrystals (sCNCs), produced by sulfuric acid-assisted hydrolysis of cellulose, is currently the predominant form of this class of nanomaterial; its utilization leads the way in terms of CNC commercialization activities and industrial applications. The functional properties, including high crystallinity, colloidal stability, and uniform nanoscale dimensions, can also be attained through carboxylated cellulose nanocrystals (cCNCs). Herein, we review recent progress in methods and feedstock materials for producing cCNCs, describe their functional properties, and discuss the initial successes in their applications. Comparisons are made to sCNCs to highlight some of the inherent advantages that cCNCs may possess in similar applications.
- 22 June 2021
- Published by MDPI AG in Nanomaterials
- Vol. 11 (7) , 1641
Open AccessPreparation and Surface Functionalization of Carboxylated Cellulose Nanocrystals
In recent years, cellulose nanocrystals (CNCs) have emerged as a leading biomass-based nanomaterial owing to their unique functional properties and sustainable resourcing. Sulfated cellulose nanocrystals (sCNCs), produced by sulfuric acid-assisted hydrolysis of cellulose, is currently the predominant form of this class of nanomaterial; its utilization leads the way in terms of CNC commercialization activities and industrial applications. The functional properties, including high crystallinity, colloidal stability, and uniform nanoscale dimensions, can also be attained through carboxylated cellulose nanocrystals (cCNCs). Herein, we review recent progress in methods and feedstock materials for producing cCNCs, describe their functional properties, and discuss the initial successes in their applications. Comparisons are made to sCNCs to highlight some of the inherent advantages that cCNCs may possess in similar applications.
- Open Access
- 12 February 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (2) , 257
Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model
Cancer remains a leading cause of morbidity and mortality worldwide. While novel treatments have improved survival outcomes for some patients, new treatment modalities/platforms are needed to combat a wider variety of tumor types. Cancer vaccines harness the power of the immune system to generate targeted tumor-specific immune responses. Liposomes composed of glycolipids derived from archaea (i.e., archaeosomes) have been shown to be potent adjuvants, inducing robust, long-lasting humoral and cell-mediated immune responses to a variety of antigens. Herein, we evaluated the ability of archaeosomes composed of sulfated lactosyl archaeol (SLA), a semi-synthetic archaeal glycolipid, to enhance the immunogenicity of a synthetic long peptide-based vaccine formulation containing the dominant CD8+ T cell epitope, SIINFEKL, from the weakly immunogenic model antigen ovalbumin. One advantage of immunizing with long peptides is the ability to include multiple epitopes, for example, the long peptide antigen was also designed to include the immediately adjacent CD4+ epitope, TEWTSSNVMEER. SLA archaeosomes were tested alone or in combination with the toll-like receptor 3 (TLR3) agonist Poly(I:C). Overall, SLA archaeosomes synergized strongly with Poly(I:C) to induce robust antigen-specific CD8+ T cell responses, which were highly functional in an in vivo cytolytic assay. Furthermore, immunization with this vaccine formulation suppressed tumor growth and extended mouse survival in a mouse melanoma tumor model. Overall, the combination of SLA archaeosomes and Poly(I:C) appears to be a promising adjuvant system when used along with long peptide-based antigens targeting cancer.
- 12 February 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (2) , 257
Open AccessSulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model
Cancer remains a leading cause of morbidity and mortality worldwide. While novel treatments have improved survival outcomes for some patients, new treatment modalities/platforms are needed to combat a wider variety of tumor types. Cancer vaccines harness the power of the immune system to generate targeted tumor-specific immune responses. Liposomes composed of glycolipids derived from archaea (i.e., archaeosomes) have been shown to be potent adjuvants, inducing robust, long-lasting humoral and cell-mediated immune responses to a variety of antigens. Herein, we evaluated the ability of archaeosomes composed of sulfated lactosyl archaeol (SLA), a semi-synthetic archaeal glycolipid, to enhance the immunogenicity of a synthetic long peptide-based vaccine formulation containing the dominant CD8+ T cell epitope, SIINFEKL, from the weakly immunogenic model antigen ovalbumin. One advantage of immunizing with long peptides is the ability to include multiple epitopes, for example, the long peptide antigen was also designed to include the immediately adjacent CD4+ epitope, TEWTSSNVMEER. SLA archaeosomes were tested alone or in combination with the toll-like receptor 3 (TLR3) agonist Poly(I:C). Overall, SLA archaeosomes synergized strongly with Poly(I:C) to induce robust antigen-specific CD8+ T cell responses, which were highly functional in an in vivo cytolytic assay. Furthermore, immunization with this vaccine formulation suppressed tumor growth and extended mouse survival in a mouse melanoma tumor model. Overall, the combination of SLA archaeosomes and Poly(I:C) appears to be a promising adjuvant system when used along with long peptide-based antigens targeting cancer.
- Open Access
- 2 February 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (2) , 205
The Synergistic Effects of Sulfated Lactosyl Archaeol Archaeosomes When Combined with Different Adjuvants in a Murine Model
Archaeosomes, composed of sulfated lactosyl archaeol (SLA) glycolipids, have been proven to be an effective vaccine adjuvant in multiple preclinical models of infectious disease or cancer. SLA archaeosomes are a promising adjuvant candidate due to their ability to strongly stimulate both humoral and cytotoxic immune responses when simply admixed with an antigen. In the present study, we evaluated whether the adjuvant effects of SLA archaeosomes could be further enhanced when combined with other adjuvants. SLA archaeosomes were co-administered with five different Toll-like Receptor (TLR) agonists or the saponin QS-21 using ovalbumin as a model antigen in mice. Both humoral and cellular immune responses were greatly enhanced compared to either adjuvant alone when SLA archaeosomes were combined with either the TLR3 agonist poly(I:C) or the TLR9 agonist CpG. These results were also confirmed in a separate study using Hepatitis B surface antigen (HBsAg) and support the further evaluation of these adjuvant combinations.
- 2 February 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (2) , 205
Open AccessThe Synergistic Effects of Sulfated Lactosyl Archaeol Archaeosomes When Combined with Different Adjuvants in a Murine Model
Archaeosomes, composed of sulfated lactosyl archaeol (SLA) glycolipids, have been proven to be an effective vaccine adjuvant in multiple preclinical models of infectious disease or cancer. SLA archaeosomes are a promising adjuvant candidate due to their ability to strongly stimulate both humoral and cytotoxic immune responses when simply admixed with an antigen. In the present study, we evaluated whether the adjuvant effects of SLA archaeosomes could be further enhanced when combined with other adjuvants. SLA archaeosomes were co-administered with five different Toll-like Receptor (TLR) agonists or the saponin QS-21 using ovalbumin as a model antigen in mice. Both humoral and cellular immune responses were greatly enhanced compared to either adjuvant alone when SLA archaeosomes were combined with either the TLR3 agonist poly(I:C) or the TLR9 agonist CpG. These results were also confirmed in a separate study using Hepatitis B surface antigen (HBsAg) and support the further evaluation of these adjuvant combinations.